- Home
- CYTK vs ELAN Comparison
CYTK vs ELAN Comparison
Compare CYTK & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTK
- ELAN
- Stock Information
- Founded
- CYTK 1997
- ELAN 1954
- Country
- CYTK United States
- ELAN United States
- Employees
- CYTK N/A
- ELAN N/A
- Industry
- CYTK Biotechnology: Pharmaceutical Preparations
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- CYTK Health Care
- ELAN Health Care
- Exchange
- CYTK Nasdaq
- ELAN Nasdaq
- Market Cap
- CYTK 6.0B
- ELAN 6.3B
- IPO Year
- CYTK 2004
- ELAN 2018
- Fundamental
- Price
- CYTK $47.67
- ELAN $13.41
- Analyst Decision
- CYTK Buy
- ELAN Buy
- Analyst Count
- CYTK 16
- ELAN 6
- Target Price
- CYTK $83.67
- ELAN $17.00
- AVG Volume (30 Days)
- CYTK 1.2M
- ELAN 4.4M
- Earning Date
- CYTK 11-06-2024
- ELAN 11-07-2024
- Dividend Yield
- CYTK N/A
- ELAN N/A
- EPS Growth
- CYTK N/A
- ELAN N/A
- EPS
- CYTK N/A
- ELAN 0.41
- Revenue
- CYTK $3,219,000.00
- ELAN $4,454,000,000.00
- Revenue This Year
- CYTK N/A
- ELAN $2.22
- Revenue Next Year
- CYTK $911.39
- ELAN $2.77
- P/E Ratio
- CYTK N/A
- ELAN $32.20
- Revenue Growth
- CYTK N/A
- ELAN 1.99
- 52 Week Low
- CYTK $30.68
- ELAN $11.40
- 52 Week High
- CYTK $110.25
- ELAN $18.80
- Technical
- Relative Strength Index (RSI)
- CYTK 34.50
- ELAN 47.80
- Support Level
- CYTK $49.64
- ELAN $13.15
- Resistance Level
- CYTK $59.39
- ELAN $14.71
- Average True Range (ATR)
- CYTK 2.37
- ELAN 0.51
- MACD
- CYTK -0.69
- ELAN 0.02
- Stochastic Oscillator
- CYTK 0.93
- ELAN 43.96
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.